U.S. Opioid Pain Management Market

This research service provides an indepth analysis of factors affecting the growth of the U.S. opioid pain management market over the period 2006-2016. Included is a disease overview, product analysis, total market revenue forecasts, product revenue forecasts, patient forecasts, and market share analysis. The market is segmented by duration of action: long-acting opioids and short-acting opioids. Major market challlenges, drivers, and restraints and identified and discussed. Included are examinations of therapeutic candidates in the opioid pain management pipeline by phase.
Published: 12 Jul 2010

This Frost & Sullivan research service titled U.S. Opioid Pain Management Market provides an in-depth analysis of the market drivers and restraints, industry trends, and competitive environment in addition to the challenges and issues faced by market participants in the long-acting and short-acting pain management opioids market.

This analysis is available through our Pharmaceutical & Biotechnology Growth Partnership Services program. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services program ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth. For more information on this custom subscription service, please click here.

Market Overview

U.S. Opioid Pain Management Market Offers Financial and Therapeutic Potential

The U.S. opioid pain management market generated revenues of $11,063.3 million in 2009 and is expected to reach $15,330.0 million in 2016. Many pain management experts consider opioids the best medication available for managing moderate to severe pain as well as cancer pain. The ineffectiveness of non-opioids in the treatment of pain has boosted market growth. Evidence points to the fact that opioids have been highly effective in the treatment of certain types of pain. With the rapid growth of the ageing population, the prevalence of painful conditions has escalated. According to the U.S. Census Bureau, the fastest growing segments of the U.S. population are the older age brackets. "This population segment presents the greatest risk for painful conditions such as osteoarthritis, rheumatoid arthritis, and hip/back problems," notes the analyst of this research service. "Trends indicate that this population segment will increase by 22.1 percent from 39.5 million in 2009 to 48.2 million in 2016, widening the scope for the market." The high incidence of certain diseases, particularly cancer and arthritis, is also likely to help spearhead the growth in this domain.

Although the prospects for the market look bright, there are some aspects clouding the landscape. Despite their benefits, opioids are known to have side effects that can be magnified when taken with other medications. Adverse reactions include respiratory disorders, depression, confusion, hallucination, urticaria, bradycardia, tachycardia, opioid-induced hyperalgesia, or even death. Furthermore, concerns over safety have required certain opioids to have risk evaluation management strategies (REMS) in place. Adverse side effects are expected to prevent patients from maintaining a short- or long-term regimen of opioids for managing pain. Apart from this, the FDA panel’s proposal to ban opioid/acetaminophen combinations has curtailed market expansion. The potential for abuse of opioids has also restrained market growth. Prescription medications are the most abused drugs in the United States. "The abuse of opioids has been rising during the past five years, while abuse of illicit drugs has remained stable," says the analyst. "Consequently, scrutiny is growing as opioids are considered controlled substances by both the state and federal governments."

Going forward, the market is likely to be energized by the launch of seven new drugs. The continued development of abuse-resistant opioid medication formulations will help alleviate concerns over the use of these medications. NUCYNTA is poised to be the top-selling opioid medication in 2016. In the future, the largest revenue contributor in the total market is expected to be the short-acting opioid market segment.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

  • Long-acting opioids
  • Short-acting opioids

Frost & Sullivan Growth Partnership Services

Frost & Sullivan's Growth Partnership Services empower companies to accelerate their growth by achieving top-line improvements and bottom-line results. This is accomplished by helping our clients execute successful growth strategies and providing their Growth Teams™ with the skills, know-how, and tools to generate growth opportunities, evaluate these opportunities to create a growth pipeline, and implement a growth strategy to deliver measurable business results.

Our growth solutions support the entire growth process:

TEAM Research

is a program that furnishes clients with access to market research, competitive intelligence, financial benchmarking, and market strategies and analysis, and provides access to industry experts to aid in generating growth opportunities.

Growth Consulting Services

unite clients with our industry experts to evaluate opportunities and develop customized strategies and business plans to drive top-line revenue and margin growth.

Growth Team Membership™

is a career-focused offering that was developed to address the unique challenges that senior executives face when implementing strategies to achieve aggressive corporate growth targets.

Features of this Research

Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..